VIDEO: Post-transplant consolidation with nivolumab, brentuximab shows promise in Hodgkin lymphoma
Click Here to Manage Email Alerts
Consolidation with nivolumab and brentuximab vedotin after autologous hematopoietic cell transplantation showed promise in patients with high-risk Hodgkin lymphoma, according to a presentation at the ASH Annual Meeting and Exposition.
“I think this is appealing,” Ann S. LaCasce, MD, MSc, of Dana-Farber Cancer Institute, said in a video interview. “What is going to change moving forward is more and more patients are probably going to be exposed to brentuximab in the front-line setting and I think that’s going to impact significantly on how we think about subsequent consolidation or transplant options.”
Collapse
Herrera AF, et al. Abstract 472. Presented at: ASH Annual Meeting and Exposition (virtual meeting); Dec. 5-8, 2020.
Click Here to Manage Email Alerts